MARKET

OCX

OCX

Oncocyte Corporation
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.040
+0.020
+1.96%
After Hours: 1.000 -0.04 -3.85% 18:08 05/27 EDT
OPEN
1.020
PREV CLOSE
1.020
HIGH
1.100
LOW
0.9599
VOLUME
476.04K
TURNOVER
0
52 WEEK HIGH
6.25
52 WEEK LOW
0.9599
MARKET CAP
123.25M
P/E (TTM)
-1.3535
1D
5D
1M
3M
1Y
5Y
BRIEF-Oncocyte Presents Determaio™ Data At Asco 2022 Supporting The Test’S Potential To Expand The Clinical Use Of Immunotherapy
reuters.com · 1d ago
Oncocyte Presents DetermaIO Data At ASCO 2022 Supporting Test's Potential To Expand Clinical Use Of Immunotherapy
Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey,
Benzinga · 1d ago
Oncocyte Presents DetermaIO™ Data at ASCO 2022 Supporting the Test’s Potential to Expand the Clinical Use of Immunotherapy
DetermaIO identifies responders to immunotherapy among the 95% of patients with colon cancer currently ineligible for treatment based on existing biomarker, addressing a significant unmet need DetermaIO test now validated by 10 studies in six tumor types a...
GlobeNewswire · 1d ago
Stephens Downgrades OncoCyte to Equalweight From Overweight, Adjusts Price Target to $1.25 From $2
MT Newswires · 4d ago
Piper Sandler Trims OncoCyte's Price Target to $1.40 From $1.80, Maintains Overweight Rating
MT Newswires · 05/16 11:07
Expert Ratings for OncoCyte
Within the last quarter, OncoCyte (NASDAQ:OCX) has observed the following analyst ratings:
Benzinga · 05/12 16:10
Needham Adjusts OncoCyte's Price Target to $2.25 From $4 on 'Peer Multiple Compression,' Reiterates Buy Rating
MT Newswires · 05/12 06:37
BRIEF-OncoCyte Board Has Appointed Andrew Arno As Chairman Of Board
reuters.com · 05/11 22:00
More
No Data
Learn about the latest financial forecast of OCX. Analyze the recent business situations of Oncocyte Corporation through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

28.57%Strong Buy
57.14%Buy
14.29%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average OCX stock price target is 3.275 with a high estimate of 6.00 and a low estimate of 1.400.
High6.00
Average3.275
Low1.400
Current 1.040
EPS
Actual
Estimate
-0.12-0.09-0.06-0.03
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 112
Institutional Holdings: 58.72M
% Owned: 49.54%
Shares Outstanding: 118.51M
TypeInstitutionsShares
Increased
28
2.33M
New
11
415.61K
Decreased
30
2.22M
Sold Out
17
1.65M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.72%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
Non-Executive Chairman/Independent Director
Andrew Arno
President/Chief Executive Officer/Director
Ronald Andrews
Chief Financial Officer
Mitchell Levine
Chief Operating Officer
Gisela Paulsen
Chief Accounting Officer/Vice President/Controller
Li Yu
Other
Douglas Ross
Other
Padma Sundar
Independent Director
Jennifer Carter
Independent Director
Melinda Griffith
Independent Director
Alfred Kingsley
Independent Director
Andrew Last
Independent Director
Cavan Redmond
No Data
No Data
About OCX
Oncocyte Corporation is a molecular diagnostics company. The Company is engaged in developing and commercializing laboratory-developed tests (LDTs) to serve unmet medical needs across the cancer care continuum. The LTDs provide actionable information to physicians and patients to optimize treatment decisions, including the selection of immunotherapy. The Company focuses on the development of a non-invasive confirmatory blood test for lung cancer called DetermaDx. The DetermaDx is the test to predict a post-surgery patient’s risk of cancer recurrence and their response to chemotherapy in early-stage lung cancer. Its development pipeline includes TheraSure CNI Monitor, which is a blood-based test for immunotherapy monitoring, and TheraSure Transplant Monitor, a solid organ transplantation monitoring test. Its other DetermaIO, DetermaCNI, DetermaMx, Keytruda, Opdivo, Tecentriq and Imfinzi.

Webull offers kinds of OncoCyte Corp stock information, including NASDAQ:OCX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OCX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OCX stock methods without spending real money on the virtual paper trading platform.